$NUVB
Nuvation Bio Inc. Stock $nuvb

$nuvb Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-K Financial Statement

#000095017023008180 Filed on March 15, 2023

Income Statement

Concept	2022 Q4	2022	2021
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.364M	$31.82M	$24.28M
YoY Change	-3.19%	31.04%	121.74%
% of Gross Profit
Research & Development	$9.571M	$87.82M	$69.04M
YoY Change	-56.5%	27.2%	111.75%
% of Gross Profit
Depreciation & Amortization	$49.00K	$199.0K	$184.0K
YoY Change	13.95%	8.15%	84.0%
% of Gross Profit
Operating Expenses	$16.94M	$119.7M	$93.32M
YoY Change	-42.8%	28.31%	114.27%
Operating Profit		-$119.7M	-$93.32M
YoY Change		28.31%	114.27%
Interest Expense	$3.394M	$6.220M	$2.883M
YoY Change	343.08%	115.75%	33.47%
% of Operating Profit
Other Income/Expense, Net	$96.00K	$15.54M	$6.470M
YoY Change	-97.41%	140.11%	241.97%
Pretax Income	-$20.85M	-$104.2M	-$86.85M
YoY Change	-17.06%	19.98%	108.47%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$20.85M	-$104.2M	-$86.85M
YoY Change	-17.06%	19.98%	108.47%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.48	-$0.44
Diluted Earnings Per Share	-$0.10	-$0.48	-$438.9K
COMMON SHARES
Basic Shares Outstanding	218.4M	216.7K	197.9K
Diluted Shares Outstanding		216.7K	197.9K

Balance Sheet

Concept	2022 Q4	2022	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$661.0M	$661.0M	$765.4M
YoY Change	-13.64%	-13.64%	254.68%
Cash & Equivalents	$101.1M	$101.1M	$132.4M
Short-Term Investments	$559.9M	$559.9M	$633.0M
Other Short-Term Assets	$3.819M	$3.819M	$3.642M
YoY Change	4.86%	4.86%	-4.16%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$667.3M	$667.3M	$772.1M
YoY Change	-13.57%	-13.57%	249.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$894.0K	$4.685M	$3.657M
YoY Change	13.74%	28.11%	422.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$138.0K	$138.0K	$421.0K
YoY Change	-67.22%	-67.22%	5.25%
Other Assets	$0.00
YoY Change
Total Long-Term Assets	$4.823M	$4.823M	$4.078M
YoY Change	18.27%	18.27%	270.73%
TOTAL ASSETS
Total Short-Term Assets	$667.3M	$667.3M	$772.1M
Total Long-Term Assets	$4.823M	$4.823M	$4.078M
Total Assets	$672.1M	$672.1M	$776.2M
YoY Change	-13.4%	-13.4%	249.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.139M	$2.139M	$3.925M
YoY Change	-45.5%	-45.5%	78.41%
Accrued Expenses	$9.816M	$11.02M	$13.00M
YoY Change	-19.12%	-15.22%	195.45%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.16M	$13.16M	$16.93M
YoY Change	-22.24%	-22.24%	156.44%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.904M	$3.904M	$13.23M
YoY Change	-70.49%	-70.49%	6514.5%
Total Long-Term Liabilities	$3.904M	$3.904M	$13.23M
YoY Change	-70.49%	-70.49%	6514.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.16M	$13.16M	$16.93M
Total Long-Term Liabilities	$3.904M	$3.904M	$13.23M
Total Liabilities	$17.07M	$17.07M	$30.15M
YoY Change	-43.41%	-43.41%	350.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$267.0M
YoY Change	64.0%
Common Stock	$927.6M
YoY Change	1.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$655.1M	$655.1M	$746.0M
YoY Change
Total Liabilities & Shareholders Equity	$672.1M	$672.1M	$776.2M
YoY Change	-13.4%	-13.4%	249.93%

Cashflow Statement

Concept	2022 Q4	2022	2021
OPERATING ACTIVITIES
Net Income	-$20.85M	-$104.2M	-$86.85M
YoY Change	-17.06%	19.98%	108.47%
Depreciation, Depletion And Amortization	$49.00K	$199.0K	$184.0K
YoY Change	13.95%	8.15%	84.0%
Cash From Operating Activities	-$16.17M	-$96.10M	-$68.20M
YoY Change	-31.14%	40.91%	86.7%
INVESTING ACTIVITIES
Capital Expenditures	$65.00K	$370.0K	-$282.0K
YoY Change	-148.15%	-231.21%	88.0%
Acquisitions
YoY Change
Other Investing Activities	-$21.76M	$63.83M	-$454.4M
YoY Change	-88.49%	-114.05%	547.46%
Cash From Investing Activities	-$21.83M	$63.46M	-$454.7M
YoY Change	-88.47%	-113.96%	546.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	407.0K	1.327M	625.5M
YoY Change	-24.35%	-99.79%	369.84%
NET CHANGE
Cash From Operating Activities	-16.17M	-96.10M	-68.20M
Cash From Investing Activities	-21.83M	63.46M	-454.7M
Cash From Financing Activities	407.0K	1.327M	625.5M
Net Change In Cash	-37.59M	-31.32M	102.7M
YoY Change	-82.29%	-130.51%	290.58%
FREE CASH FLOW
Cash From Operating Activities	-$16.17M	-$96.10M	-$68.20M
Capital Expenditures	$65.00K	$370.0K	-$282.0K
Free Cash Flow	-$16.23M	-$96.47M	-$67.92M
YoY Change	-30.47%	42.04%	86.7%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001811063
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-39351
CY2022	dei	Entity Registrant Name EntityRegistrantName	NUVATION BIO INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-0862255
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	1500 Broadway
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1401
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10036
CY2022	dei	City Area Code CityAreaCode	332
CY2022	dei	Local Phone Number LocalPhoneNumber	208-6102
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	468975754000
CY2022	dei	Auditor Firm AuditorFirmId	185
CY2022	dei	Auditor Name AuditorName	KPMG LLP
CY2022	dei	Auditor Location AuditorLocation	Short Hills, New Jersey
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	101099000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	132423000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3819000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3642000
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	559915000
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	632969000
CY2022Q4	nuvb	Interest Receivable On Marketable Securities Current InterestReceivableOnMarketableSecuritiesCurrent	2485000
CY2021Q4	nuvb	Interest Receivable On Marketable Securities Current InterestReceivableOnMarketableSecuritiesCurrent	3039000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	667318000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	772073000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	894000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	786000
CY2022Q4	nuvb	Lease Security Deposit Noncurrent LeaseSecurityDepositNoncurrent	138000
CY2021Q4	nuvb	Lease Security Deposit Noncurrent LeaseSecurityDepositNoncurrent	421000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3791000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2871000
CY2022Q4	us-gaap	Assets Assets	672141000
CY2021Q4	us-gaap	Assets Assets	776151000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2139000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3925000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1206000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	863000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9816000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12137000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13161000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16925000
CY2022Q4	nuvb	Warrant Liability WarrantLiability	850000
CY2021Q4	nuvb	Warrant Liability WarrantLiability	11037000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3054000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2192000
CY2022Q4	us-gaap	Liabilities Liabilities	17065000
CY2021Q4	us-gaap	Liabilities Liabilities	30154000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	218632699
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	218632699
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	217948568
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	217948568
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	927604000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	909985000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-267002000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-162803000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5526000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1185000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	655076000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	745997000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	672141000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	776151000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	87815000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	69037000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31919000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	24281000
CY2022	us-gaap	Operating Expenses OperatingExpenses	119734000
CY2021	us-gaap	Operating Expenses OperatingExpenses	93318000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-119734000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-93318000
CY2022	us-gaap	Interest Income Other InterestIncomeOther	7448000
CY2021	us-gaap	Interest Income Other InterestIncomeOther	2963000
CY2022	us-gaap	Professional Fees ProfessionalFees	872000
CY2021	us-gaap	Professional Fees ProfessionalFees	644000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-10187000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4231000
CY2022	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-1228000
CY2021	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-80000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	15535000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6470000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-104199000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-86848000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-104199000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-86848000
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	216721
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	216721
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	197887
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	197887
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-104199000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-86848000
CY2022	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	-4341000
CY2021	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	-2742000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-108540000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-89590000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	215084000
CY2021	nuvb	Issuance And Exchange Of Common Stock Net Of Issuance Cost Upon Business Combination Transaction Value IssuanceAndExchangeOfCommonStockNetOfIssuanceCostUponBusinessCombinationTransactionValue	606690000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-3787000
CY2021	nuvb	Issuance Of Common Stock For Purchase Under Espp Value IssuanceOfCommonStockForPurchaseUnderEsppValue	-308000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	450000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9268000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-86848000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2742000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	745997000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	939000
CY2022	nuvb	Issuance Of Common Stock For Purchase Under Espp Value IssuanceOfCommonStockForPurchaseUnderEsppValue	-388000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16292000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-104199000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4341000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	655076000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-104199000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-86848000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-3787000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	16292000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	9268000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	199000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	184000
CY2022	nuvb	Non Cash Lease Expense NonCashLeaseExpense	285000
CY2021	nuvb	Non Cash Lease Expense NonCashLeaseExpense	184000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-10187000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4231000
CY2022	nuvb	Amortization Of Premium On Marketable Securities AmortizationOfPremiumOnMarketableSecurities	-3671000
CY2021	nuvb	Amortization Of Premium On Marketable Securities AmortizationOfPremiumOnMarketableSecurities	-4593000
CY2022	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-1228000
CY2021	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-80000
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-50000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	177000
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2416000
CY2022	us-gaap	Increase Decrease In Interest And Dividends Receivable IncreaseDecreaseInInterestAndDividendsReceivable	-554000
CY2021	us-gaap	Increase Decrease In Interest And Dividends Receivable IncreaseDecreaseInInterestAndDividendsReceivable	1947000
CY2022	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	283000
CY2021	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	0
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1786000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1861000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2321000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	7452000
CY2022	nuvb	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	0
CY2021	nuvb	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	-157000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-96108000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-68190000
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	520307000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	609300000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	584121000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	154913000
CY2022	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	370000
CY2021	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	282000
CY2022	us-gaap	Proceeds From Sale Of Other Property Plant And Equipment ProceedsFromSaleOfOtherPropertyPlantAndEquipment	13000
CY2021	us-gaap	Proceeds From Sale Of Other Property Plant And Equipment ProceedsFromSaleOfOtherPropertyPlantAndEquipment	0
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	63457000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-454669000
CY2022	us-gaap	Business Combination Separately Recognized Transactions Net Gains And Losses BusinessCombinationSeparatelyRecognizedTransactionsNetGainsAndLosses	0
CY2021	us-gaap	Business Combination Separately Recognized Transactions Net Gains And Losses BusinessCombinationSeparatelyRecognizedTransactionsNetGainsAndLosses	-624769000
CY2022	nuvb	Issuance Of Common Stock For Purchase Under Espp Value IssuanceOfCommonStockForPurchaseUnderEsppValue	-388000
CY2021	nuvb	Issuance Of Common Stock For Purchase Under Espp Value IssuanceOfCommonStockForPurchaseUnderEsppValue	-308000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	939000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	450000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1327000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	625527000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-31324000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	102668000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132423000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29755000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	101099000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132423000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2171000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3917000
CY2022	us-gaap	Stock Issued1 StockIssued1	0
CY2021	us-gaap	Stock Issued1 StockIssued1	3787000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-267000000.0
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-96100000
CY2022Q4	nuvb	Cash And Cash Equivalents And Marketable Securities CashAndCashEquivalentsAndMarketableSecurities	661000000.0
CY2022Q4	nuvb	Panacea Equity At Effective Time PanaceaEquityAtEffectiveTime	606690000
CY2022	nuvb	Share Outstanding Prior To Business Combination ShareOutstandingPriorToBusinessCombination	18456250
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue and expenses during the year. Accordingly, actual results could differ from those estimates and those differences could be significant. Significant estimates and assumptions reflected in the accompanying consolidated financial statements include, but are not limited to, the fair value of in-process research and development acquired, warrant liabilities, leases, stock options granted and depreciation expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to cash and cash equivalents credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings. Marketable securities consist primarily of government and corporate bonds, municipal securities and exchange traded fund with fixed interest rates. Exposure to credit risk of marketable securities is reduced by maintaining a diverse portfolio and monitoring their credit ratings.</span></p>
CY2022	nuvb	Redemption Of Share Prior To Business Combination RedemptionOfSharePriorToBusinessCombination	-3350
CY2022	nuvb	Conversion Of Shares Related To Merger ConversionOfSharesRelatedToMerger	0
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5787472
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.50
CY2022	us-gaap	Sale Of Stock Description Of Transaction SaleOfStockDescriptionOfTransaction	the exercise of the Warrants may be settled in cash upon the occurrence of a tender offer or exchange that involves more than 50% of the outstanding shares of the Company’s common stock.
CY2022	nuvb	Business Combination Common Stock Shares Outstanding BusinessCombinationCommonStockSharesOutstanding	18452900
CY2022	nuvb	Shares Issued Pursuant To Pipe Financing SharesIssuedPursuantToPIPEFinancing	47655000
CY2022	nuvb	Shares Issued Pursuant To Forward Purchase SharesIssuedPursuantToForwardPurchase	2500000
CY2022	nuvb	Issuance Of Shares Upon Business Combination IssuanceOfSharesUponBusinessCombination	68607900
CY2022	nuvb	Business Combination Conversion Of Redeemable Convertible Preferred Stock BusinessCombinationConversionOfRedeemableConvertiblePreferredStock	68097805
CY2022	nuvb	Cash At Bank And Cash Held In Trust Account CashAtBankAndCashHeldInTrustAccount	144642000
CY2022	nuvb	Proceeds From Pipe Investment And Forward Purchase Agreement ProceedsFromPIPEInvestmentAndForwardPurchaseAgreement	501550000
CY2022	nuvb	Payment Of Underwriter Fees And Other Offering Costs PaymentOfUnderwriterFeesAndOtherOfferingCosts	23913000
CY2022	nuvb	Payment To Common Stockholders Due To Exercised Right To Redeem Shares PaymentToCommonStockholdersDueToExercisedRightToRedeemShares	32000
CY2022	nuvb	Proceeds From Business Combination Net ProceedsFromBusinessCombinationNet	622247000
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets	312000
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Financial Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities	-601000
CY2022Q4	nuvb	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Warrant Liability BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantLiability	-15268000
CY2022	nuvb	Conversion Of Old Nuvation Class A Common Stock ConversionOfOldNuvationClassACommonStock	23299337
CY2022	nuvb	Conversion Of Old Nuvation Class B Common Stock ConversionOfOldNuvationClassBCommonStock	57645013
CY2022	nuvb	Conversion Of Founder Shares ConversionOfFounderShares	0
CY2022	nuvb	Number Of Common Shares Outstanding After Business Combination NumberOfCommonSharesOutstandingAfterBusinessCombination	217650055
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	68311000
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	559915000
CY2022Q4	nuvb	Total Financial Assets TotalFinancialAssets	628226000
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	850000
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	84708000
CY2021Q4	us-gaap	Marketable Securities MarketableSecurities	632969000
CY2021Q4	nuvb	Total Financial Assets TotalFinancialAssets	717677000
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	11037000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	633752000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	86000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5612000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	628226000
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	719028000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	363000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1714000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	717677000
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	9000
CY2021	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	88000
CY2022	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	-1065000
CY2021	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	2000
CY2022	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-1056000
CY2021	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	86000
CY2022	us-gaap	Equity Securities Fv Ni Realized Loss EquitySecuritiesFvNiRealizedLoss	172000
CY2021	us-gaap	Equity Securities Fv Ni Realized Loss EquitySecuritiesFvNiRealizedLoss	0
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Loss EquitySecuritiesFvNiUnrealizedLoss	0
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Loss EquitySecuritiesFvNiUnrealizedLoss	166000
CY2022	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-172000
CY2021	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-166000
CY2022	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-1228000
CY2021	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-80000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	253605000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1650000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	212814000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	3962000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	466419000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	5612000
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	523282000
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1714000
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	523282000
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1714000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	478259000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	81656000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis	559915000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1352000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1077000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	458000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	291000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	894000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	786000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	200000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	200000
CY2022Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	5362000
CY2021Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	5086000
CY2022Q4	us-gaap	Accrued Employee Benefits Current And Noncurrent AccruedEmployeeBenefitsCurrentAndNoncurrent	3987000
CY2021Q4	us-gaap	Accrued Employee Benefits Current And Noncurrent AccruedEmployeeBenefitsCurrentAndNoncurrent	6165000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	236000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	288000
CY2022Q4	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	112000
CY2021Q4	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	402000
CY2022Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	119000
CY2021Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	196000
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	9816000
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	12137000
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	1500000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	1300000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	0
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	0
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1200000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1200000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1422000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1495000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1071000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	631000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	81000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4700000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	440000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4260000
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.060
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y4M2D
CY2022	us-gaap	Common Stock Conversion Features CommonStockConversionFeatures	The holder of the Class B Common Stock had the option to convert each share into one fully paid share of Class A Common Stock at any time. Upon the earlier of the date (i) the Founder of the Company owns in aggregate fewer than 220,571,000 shares of Common Stock, (ii) the Founder no longer serves as the Company’s Chief Executive Office or (iii) the Founder’s death or disability, each share of Common B Common Stock shall automatically convert to one fully paid share of Class A Common Stock and the Company shall not issue any additional shares of Class B Common Stock. Each share of Class B Common Stock shall automatically convert into one paid share of Class A Common Stock upon any sale or disposition of a share of Class B Common Stock.
CY2022	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	600000
CY2021	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	400000
CY2022	us-gaap	Market Risk Benefit Change In Fair Value Gain Loss MarketRiskBenefitChangeInFairValueGainLoss	10200000
CY2022	nuvb	Fair Value Equity Level1 To Level2 Or Level3 Transfers Description FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription	no
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1185000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1557000
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-5569000
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-2656000
CY2022	nuvb	Realized Loss On Marketable Securities RealizedLossOnMarketableSecurities	1228000
CY2021	nuvb	Realized Loss On Marketable Securities RealizedLossOnMarketableSecurities	-86000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5526000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1185000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16292000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9268000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	3.00
CY2022	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.03
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	850000
CY2021Q4	nuvb	Changes In Liabilities Classified In Level3 Of Fair Value Hierarchy ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy	406000
CY2022	nuvb	Change In Fair Value Of Private Warrants Liability Recognized In Earnings ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings	-369000
CY2022Q4	nuvb	Changes In Liabilities Classified In Level3 Of Fair Value Hierarchy ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy	37000
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	2000
CY2021	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	1000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-2000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-1000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	22183000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	13442000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	11074000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3721000
CY2022Q4	nuvb	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	46260000
CY2021Q4	nuvb	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	33435000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4396000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1857000
CY2022Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	1090000
CY2021Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	1924000
CY2022Q4	nuvb	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	1165000
CY2021Q4	nuvb	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	953000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	0
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	26000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	86168000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	55358000
CY2022Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	0
CY2021Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	0
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1036000
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	896000
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	9000
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1045000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	896000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	85123000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	54462000
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0633
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.1021
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0165
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0039
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.0565
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.0159
CY2022	nuvb	Effective Income Tax Rate Reconciliation True Up EffectiveIncomeTaxRateReconciliationTrueUp	-0.0054
CY2021	nuvb	Effective Income Tax Rate Reconciliation True Up EffectiveIncomeTaxRateReconciliationTrueUp	0.0387
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0467
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0059
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0001
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2942
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3766
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2022	nuvb	Operating Loss Carryforwards Expiration OperatingLossCarryforwardsExpiration	2038
CY2022	nuvb	Tax Credit Carryforwards Expiration TaxCreditCarryforwardsExpiration	2039
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5100000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1595000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2524000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	893000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	949000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	702000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5068000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1595000
CY2022	us-gaap	Restructuring Charges RestructuringCharges	7397000
CY2022	us-gaap	Payments For Restructuring PaymentsForRestructuring	7390000
CY2022	us-gaap	Restructuring Costs RestructuringCosts	7000

Files In Submission

Name	View Source	Status
nuvb-20221231_cal.xml	Edgar Link	unprocessable
0000950170-23-008180-index-headers.html	Edgar Link	pending
0000950170-23-008180-index.html	Edgar Link	pending
0000950170-23-008180.txt	Edgar Link	pending
0000950170-23-008180-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img56386583_0.jpg	Edgar Link	pending
img56386583_1.jpg	Edgar Link	pending
img56386583_10.jpg	Edgar Link	pending
img56386583_11.jpg	Edgar Link	pending
img56386583_12.jpg	Edgar Link	pending
img56386583_13.jpg	Edgar Link	pending
img56386583_14.jpg	Edgar Link	pending
img56386583_15.jpg	Edgar Link	pending
img56386583_16.jpg	Edgar Link	pending
img56386583_17.jpg	Edgar Link	pending
img56386583_18.jpg	Edgar Link	pending
img56386583_2.jpg	Edgar Link	pending
img56386583_3.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
img56386583_4.jpg	Edgar Link	pending
img56386583_5.jpg	Edgar Link	pending
img56386583_6.jpg	Edgar Link	pending
img56386583_7.jpg	Edgar Link	pending
img56386583_8.jpg	Edgar Link	pending
img56386583_9.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nuvb-20221231.htm	Edgar Link	pending
nuvb-20221231.xsd	Edgar Link	pending
nuvb-ex23_1.htm	Edgar Link	pending
nuvb-ex31_1.htm	Edgar Link	pending
nuvb-ex31_2.htm	Edgar Link	pending
nuvb-ex32_1.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
nuvb-20221231_def.xml	Edgar Link	unprocessable
nuvb-20221231_lab.xml	Edgar Link	unprocessable
nuvb-20221231_pre.xml	Edgar Link	unprocessable
nuvb-20221231_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NUVB
Nuvation Bio Inc. Stock $nuvb

2022 Q4 Form 10-K Financial Statement

#000095017023008180 Filed on March 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NUVB Nuvation Bio Inc. Stock $nuvb

2022 Q4 Form 10-K Financial Statement

#000095017023008180 Filed on March 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NUVB
Nuvation Bio Inc. Stock $nuvb